Evidence map›Paper›PMID 18568339›Full record

ReviewPsychopharmacology2008

Realistic expectations of prepulse inhibition in translational models for schizophrenia research.

Neal R Swerdlow, Martin Weber, Ying Qu, Gregory A Light, David L Braff

Open access · bronzeAbstract readReview
In one paragraph

Review in Psychopharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 274 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
274citing papers in PubMed, 2 pooled it
22.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

274 citing papers in PubMed, 2 syntheses or guidelines pooled it, 526 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Maternal immune activation in mice recapitulates features of attention-deficit/hyperactivity disorder (ADHD) in susceptible offspring.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  7. Article
  8. Effect of Traumatic Brain Injury on Sensorimotor Gating.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2026
    Article
  9. Article
  10. Article
  11. Inhibition of Cortical Evoked Responses to Sound Pulses by Preceding Silent Gaps.Journal of the Association for Research in Otolaryngology : JARO · 2025
    Article
  12. Review
  13. Article
  14. Article
  15. Affective phenotypes in heterozygousFrontiers in genetics · 2025
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

214 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Neal R SwerdlowDepartment of Psychiatry, UCSD School of Medicine, La Jolla, CA, 92093-0804, USA, nswerdlow@ucsd.edu.
Martin Weber
Ying Qu
Gregory A Light
David L Braff
University of California San Diego · US

Funding

The Genetics of Endophenotypes and SchizophreniaR01MH065571 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BRAFF, DAVID L. · 2003 to 2013
$7.0M
SENSORY GATING &HABITUATION IN SCHIZOPHRENIAR01MH042228 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BRAFF, DAVID L. · 1987 to 2015
$6.5M
Pharmacologic augmentation of neurocognition and cognitive training in psychosisR01MH059803 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SWERDLOW, NEAL R · 1999 to 2018
$4.5M
CORTICO-STRIATAL SUBSTRATES OF DEFICIENT STARTLE GATINGR01MH053484 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SWERDLOW, NEAL R · 1997 to 2010
$2.0M
Neural Basis of Heritable DA-Mediated Gating DeficitsR01MH068366 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SWERDLOW, NEAL R · 2003 to 2010
$1.6M
Pathway(s) From Genes to Functional Deficits of Schizophrenia PatientsR01MH079777 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LIGHT, GREGORY A · 2007 to 2010
$1.4M
SENSORY GATING AND HABITUATION IN SCHIZOPHRENIAR37MH042228 · NIMH · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI BRAFF, DAVID L. · 1993 to 2002
$1.3M
A Simple Measure for Studying Sensory Gating DeficitsR01MH069589 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SWERDLOW, NEAL R · 2004 to 2007
$661k
NIMH NIH HHS MH 42228NIMH NIH HHS MH 53484NIMH NIH HHS MH 58903NIMH NIH HHS MH 65571NIMH NIH HHS MH 68366NIMH NIH HHS MH 69589NIMH NIH HHS MH 79777NIMH NIH HHS R01 MH042228NIMH NIH HHS R01 MH053484NIMH NIH HHS R01 MH059803NIMH NIH HHS R01 MH065571NIMH NIH HHS R01 MH068366NIMH NIH HHS R01 MH069589NIMH NIH HHS R01 MH079777NIMH NIH HHS R37 MH042228
6 · The paper itself

Abstract

introductionUnder specific conditions, a weak lead stimulus, or "prepulse", can inhibit the startling effects of a subsequent intense abrupt stimulus. This startle-inhibiting effect of the prepulse, termed "prepulse inhibition" (PPI), is widely used in translational models to understand the biology of brainbased inhibitory mechanisms and their deficiency in neuropsychiatric disorders. In 1981, four published reports with "prepulse inhibition" as an index term were listed on Medline; over the past 5 years, new published Medline reports with "prepulse inhibition" as an index term have appeared at a rate exceeding once every 2.7 days (n=678). Most of these reports focus on the use of PPI in translational models of impaired sensorimotor gating in schizophrenia. This rapid expansion and broad application of PPI as a tool for understanding schizophrenia has, at times, outpaced critical thinking and falsifiable hypotheses about the relative strengths vs. limitations of this measure.

objectivesThis review enumerates the realistic expectations for PPI in translational models for schizophrenia research, and provides cautionary notes for the future applications of this important research tool.

conclusionIn humans, PPI is not "diagnostic"; levels of PPI do not predict clinical course, specific symptoms, or individual medication responses. In preclinical studies, PPI is valuable for evaluating models or model organisms relevant to schizophrenia, "mapping" neural substrates of deficient PPI in schizophrenia, and advancing the discovery and development of novel therapeutics. Across species, PPI is a reliable, robust quantitative phenotype that is useful for probing the neurobiology and genetics of gating deficits in schizophrenia.

Indexed as

Models, PsychologicalSchizophrenic PsychologyAnimalsAntipsychotic AgentsDisease Models, AnimalHumansReflex, StartleSchizophreniaAntipsychotic Agents

Identifiers

PMID18568339
PMCPMC2771731
OpenAlexW2062472783

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.